Page **1** of **5** >

ADVANCINGACCESS®

for **SUNLENCA®** (lenacapavir)



PHONE: 1-800-226-2056 | FAX: 1-833-445-3234

(Monday through Friday, 9 AM–8 PM EST)

PATIENT CONFIDENTIALITY: Patient confidentiality is of primary importance to us. All patient information will remain confidential. Information may be provided to clinicians, social workers, or family members when required to complete the enrollment process and coordinate patient assistance, and to credit bureaus to determine program eligibility with your consent within this Enrollment Form.

	n, a dedicated Advancing Access prog nrough the next steps of the process an			CLEAR FORM	
1. REQUESTED PATIENT SUPP				CHECK ALL BOXES THAT APPLY 🏑	
Benefits Investigation	Co-pay Coupon Program	or Authorization and Appeals Infor	rmation	Patient Assistance Program (PAP)	
2. GILEAD MEDICATION PRES					
Product Name: SUNLENCA® (lenacapavir)					
Please indicate if you are requesting inform	mation for: Initial Dose (oral/injection)	Maintenance (injection)			
3. PATIENT INFORMATION	REQUIRED				
First Name:	Last Name:		MI:	Preferred Name:	
Address:		Apt/Unit #:	City:		
State:	ZIP Code:	Phone #: () -	_	Preferred Language:	
Email:	`	Date of Birth: / /		SSN # (Last 4 digits):	
Alternate Contact Name:		Phone #: () -	-	Relationship:	
CONTACT AUTHORIZATION					
reference to the Advancing Access progra that apply):	ne with information on my benefits and oth am or the ARx Patient Solutions Pharmacy t sage US mail etailed message, including the name of my p	 hrough the following (select all If I do not select a contact I understand that Advancin provide program communic by phone and/or through m provider Text message and data rates 		I do not select a contact preference, understand that Advancing Access will rovide program communications to me y phone and/or through my healthcare rovider ext message and data rates may apply. You can opt out of such text messages at	
4. INSURANCE INFORMATION	REQUIRED	PLEASE INCLUDE A COPY OF	THE FRC	ONT AND BACK OF INSURANCE CARD(S)	
Patient is uninsured (ie, no health insu	rance through any public or private payer)	- SEE OPTIONAL "PATIENT FINA	NCIAL INF	ORMATION" SECTION 5	
Patient is insured (Please fill out all of	the applicable insurance information below	v — Include copy [front & back] of	all insuran	ce cards, including medical and prescription.)	
PRIMARY INSURANCE					
Primary Insurance:	Is this a Medicare Part D plan? Yes No				
Plan Name:	Insurance Phone #: () –				
Subscriber Name:					
Policyholder Name:	Policyholder Relationship to Patient:				
Policy #:	Group #:	Rx Bin #:		Rx PCN #:	
SECONDARY INSURANCE (Check this box if patient has secondary insurance coverage and include a copy [front and back] of insurance cards, if available)					
Secondary Insurance: Is this a Medicare Part D plan? Yes No				No	
Plan Name:	Insurance Phone #: () –				
Subscriber Name:					
Policyholder Name:	olicyholder Name: Policyholder Relationship to Patient:				
Policy #:	Group #:	Rx Bin #:		Rx PCN #:	

THIS PAGE TO BE COMPLETED BY **PATIENT** OR **PATIENT'S REPRESENTATIVE** Page 2 of 5 < ADVANCING ACCESS® SUNLENCA® (lenacapavir) PATIENT ENROLLMENT FORM PHONE: 1-800-226-2056 | FAX: 1-833-445-3234 PATIENT NAME: DATE OF BIRTH: 1 1 5. PATIENT FINANCIAL INFORMATION (REQUIRED ONLY IF APPLYING FOR THE PATIENT ASSISTANCE PROGRAM (PAP) Current annual household income: \$ ____ (Documentation for all sources of income may be required) Number of people in household supported by current annual income: 1 2 3 4 5 Other: ____ ADDITIONAL INSURANCE INFORMATION Has the patient applied for the AIDS Drug Assistance Program (ADAP)? 🗌 Yes 🗌 No If Yes, date of application: ____ What is the ADAP status of the patient? 🗌 Not applied 📄 Pending 🔛 Wait-listed 📄 Denied (include denial letter) 🗌 Not eligible, reason:______ Yes No Has the patient applied for Medicaid? Yes No Is the patient eligible for Medicaid? If Yes, date of application: 1 If No, state reason (if denied, include a copy of the denial letter): _____ Yes No Has the patient applied for Medicare? Yes No Is the patient eligible for Medicare? If No, state reason (if denied, include a copy of the denial letter): ____ If Yes, date of application: If Yes, has the patient tried to obtain the Yes No Yes No Is the patient eligible for VA benefits? medication through the VA? Is the patient eligible for an insurance plan offered through a state insurance Yes No Has the patient applied for an insurance Yes No marketplace (also known as an exchange)? plan offered through a state insurance marketplace (also known as an exchange)? If No, state reason: ____ If Yes, date of application: APPLICANT CONSENT AND DECLARATIONS REQUIRED ONLY IF APPLYING FOR THE PAP

By signing below, I certify that all of the information provided in this application, including household income, is complete and accurate.

I understand that my prescription will be shipped directly to the prescriber's office address listed on this form (Section 7). I authorize the prescriber listed on this form, as my agent, to receive my prescription on my behalf. My prescriber, as my agent, will receive and then provide me with my prescription medication. **Note:** SUNLENCA^{*} (lenacapavir) will be shipped directly to the HCP.

I understand that program assistance will terminate if Advancing Access becomes aware of any false or inaccurate information or if this medication is no longer prescribed for me. I understand that I may only use the free product received through the PAP for my own use and personal consumption, and that I will not offer the product for sale, resale, barter, or trade.

I understand that completing this application does not ensure that I will qualify for patient assistance. If I receive free product through the PAP, I certify that I will not seek reimbursement or credit for this medication from any insurer, health plan, or government program. If I am a member of a Medicare Part D plan, I will not seek to have this medication, or any cost for items associated with it, counted as part of my out-of-pocket cost for prescription drugs. I understand that the PAP reserves the right to modify the application form, modify or discontinue this program, or terminate assistance at any time and without notice.

I authorize the PAP and its administrator to forward my prescription to a dispensing pharmacy on my behalf. Advancing Access may require me to submit proof of identity and income documentation to verify my eligibility into the Patient Assistance Program (eg, identification card, tax return, W-2, last two pay stubs, etc). I **authorize Gilead and its third-party administrator to use the information provided on this form to obtain a personal credit report about me to verify the information on this form and determine my eligibility for the PAP.**

SIGNATURE OF PATIENT or PATIENT'S AUTHORIZED REPRESENTATIVE UNDER FEDERAL OR STATE LAW (REQUIRED):			/	/
PATIENT REPRESENTATIVE'S NAME (IF SIGNING FOR THE PATIENT):	PATIENT REPRESENTATIVE'S RELATIONSHIP TO PATIENT:	PHONE #: ()	-

Page 3 of 5

PHONE: 1-800-226-2056 | FAX: 1-833-445-3234

DATE OF BIRTH:

THIS PAGE TO BE COMPLETED BY **PATIENT** OR **PATIENT'S REPRESENTATIVE**

ADVANCING ACCESS[®] SUNLENCA[®] (lenacapavir) PATIENT ENROLLMENT FORM

PATIENT NAME:

6. PATIENT AUTHORIZATION FOR USE AND DISCLOSURE OF PERSONAL HEALTH INFORMATION REQUIRED

I understand that Gilead Sciences, Inc., and its agents, contractors, and other partners ("Gilead") will need to obtain, review, use, and disclose my personal and medical information before I can receive assistance through the Advancing Access program (the "Program") and the Patient Assistance Program ("PAP"). Additional information about how Gilead may use my information can be found at https://www.gilead.com/privacy-statements.

<u>Information to Be Disclosed:</u> My personal information related to my enrollment or participation in the Program, which may include personally identifiable information and Protected Health Information ("PHI") as defined under the Health Insurance Portability and Accountability Act of 1996 ("HIPAA") as amended by the Health Information Technology for Economic and Clinical Health ("HITECH") Act (collectively Personal Information or "PI"):

- General information about me, including my name, birth date, and contact information
- Information about my medical condition, including information about my HIV-related status or treatment with this prescription medication and related medical condition
- Information about my health benefits or health insurance coverage
- Financial information (as necessary), such as my income
- All information provided on this enrollment form and otherwise provided by me to the Program or PAP

Persons Authorized to Disclose and Use My Information: I authorize the following parties to disclose my PI to Gilead and its partners:

- My healthcare providers, including any pharmacy that fills my prescription medication. I understand that my pharmacy providers may receive remuneration for disclosing my PI pursuant to this authorization
- Any health plans, including my health insurance company, or programs that provide me with healthcare benefits

I also authorize Gilead and its partners to redisclose my PI to the following parties:

- My healthcare providers, including the pharmacy that fills my prescription medication
- My health plans, including my health insurance company
- My authorized representative under federal or state law (if applicable)

Purposes for Which My Information May Be Used and Disclosed: My PI may be used and disclosed for the following purposes:

- Completing the enrollment process and verifying the information provided on my enrollment form, including confirming my identity and my use or potential use of the medication prescribed by my healthcare provider
- Establishing my eligibility for benefits from my health plan or other programs
- Providing financial assistance and reimbursement support, if I am eligible, and providing other applicable support, including information on third-party resources that may be able to assist me
- Communicating with my healthcare providers and coordinating my prescription and medication through a pharmacy or healthcare provider's office
- Contacting me to evaluate the effectiveness of the Program and/or the PAP
- Gilead's internal business purposes and audit and compliance purposes
- Confirming my receipt of the prescribed Gilead medication through the PAP based on my communication preferences above
- Deidentifying the information I provide, which means removing elements like my name and address so that I am no longer reasonably identifiable

Please continue onto next page >>>

• Meeting Gilead's legal requirements

THIS PAGE TO BE COMPLETED BY	PATIENT OR PATIENT'S RE	PRESENTATIVE Page 4 of 5 < 🗅
------------------------------	-------------------------	------------------------------

ADVANCING ACCESS® SUNLENCA® (lenacapavir) PATIENT ENROLLMENT FORM

PATIENT NAME:

PHONE: 1-800-226-2056 | FAX: 1-833-445-3234

DATE OF BIRTH:

/ /

6. PATIENT AUTHORIZATION FOR USE AND DISCLOSURE OF PERSONAL HEALTH INFORMATION (CONTINUED) REQUIRED

Other Important Points:

- I understand that I may choose not to sign this authorization. If I refuse, my eligibility for health plan benefits or ability to obtain treatment from my healthcare providers will not change, but I will not have access to the support offered by the Program and/or the PAP
- Once I sign this Patient Authorization and my PI is transmitted to Gilead and its partners, I understand that state and federal
 privacy laws may no longer protect or prohibit the redisclosure of the PI disclosed to Gilead and its partners by my healthcare
 provider or others
- I understand that I am entitled to a copy of this signed authorization and that the authorization expires on the earlier of two (2) years from the date it is signed by me or sooner if required under the laws of the state in which I live
- I understand that I may cancel this authorization at any time by notifying Gilead at 1-800-226-2056. If I cancel, Gilead will stop
 using this authorization to obtain, use, or disclose my PI after the cancellation date, but the cancellation will not affect uses or
 disclosures of any PI that have already been made pursuant to this authorization before the cancellation date

Marketing Communications Opt In (OPTIONAL): I would like to receive marketing and informational communications from Gilead related to my medical condition, treatment, and/or my prescription medication, including offers, marketing and promotional information, and educational materials, via one or more of the communications methods I agreed to above. I understand that opting in to the marketing and informational communications is not required as a condition of (i) eligibility for health plan benefits or ability to obtain treatment from my healthcare providers, (ii) enrollment in the Program or PAP, or (iii) purchasing any goods or receiving a co-pay or other support from Gilead. The marketing outreach program is separate from the PAP. NOTE: Advancing Access may communicate with me as necessary to administer the Program, including PAP, even if I do not opt in to receive marketing and informational communications from Gilead.

By checking this box, I consent to receive marketing and informational communications from Gilead (as described above) to my phone number provided, including text messages, prerecorded messages and phone calls, which may be sent via autodialer. Text and data rates may apply. I may opt out at any time by texting "STOP."

SIGNATURE OF PATIENT or PATIENT'S AUTHORIZED REPRESENTATIVE UNDER FEL	DATE:	/	/	
PATIENT REPRESENTATIVE'S NAME (IF SIGNING FOR THE PATIENT):	PATIENT REPRESENTATIVE'S RELATIONSHIP TO PATIENT:	PHONE #: ()	-

Page **5** of **5**

ADVANCING ACC	CESS [®] SUNLENCA [®] (lenacapavir) PATIENT ENROLLME	NT FORM	PHONE: 1-800-226-2	056 FAX: 1-833-445-3234	
PATIENT NAME: DATE OF BIRTH:/ /					
7. PRESCRIBER			MUST BE COMPLETED	BY A HEALTHCARE PROVIDER	
Prescriber Name:		Facility Name:			
Address:		City:	State:	ZIP Code:	
Office Contact:		Phone #: ()	– Fax #: () –	
NPI #:	NPI #: State License #: Tax ID #:				
8. DIAGNOSIS			MUST BE COMPLETED	BY A HEALTHCARE PROVIDER	
Diagnosis (Please in	clude ICD code[s]):				
	ON INFORMATION			TION FORM WHICH WILL RMACY FOR DISPENSING R	
Patient First Name:	Last Name:			Date of Birth: / /	
Is this the patient's fir	st treatment of SUNLENCA (lenacapavir)?		·		
Has the prescription	already been sent to the specialty pharmacy? Yes No (f "No," Advancing Access will se	end this prescription to the spe	cialty pharmacy for processing)	
Known medication al	lergies: (🗌 None)				
FOR PATIENTS STA	RTING SUNLENCA, CHOOSE OPTION 1 OR 2 (choose only c	ne option)	FOR PATIENTS ON MA	AINTENANCE SUNLENCA	
OPTION 1: Oral and Injection	SUNLENCA Injection 927 mg SubQ QUANTITY: 2 x 1.5 mLs REFILLS: 1 SIG: Inject 2 x 1.5 mL subcutaneously on Day 1, then repeat every 6 months (26 weeks)			ENCA on 927 mg SubQ ITY: 2 x 1.5 mLs REFILLS: 1 ect 2 x 1.5 mL subcutaneously 5 months (26 weeks)	
OPTION 2: Oral and Injection	SUNLENCA Oral 300 mg tablet QUANTITY: 5 REFILLS: 0 SIG: Take 2 tablets PO on Day 1, 2 tablets PO on Day 2, and 1 tablet PO on Day 8 SUNLENCA Injection 927 mg SubQ QUANTITY: 2 x 1.5 mLs REFILLS: 1 SIG: Inject 2 x 1.5 mL subcutaneously on Day 15, then repeat every 6 months (26 weeks)			y o monulo (20 weeks)	
REQUIRED	Anticipated Start Date: / / NOTE: Both SUNLENCA oral and injection doses will be shipped directly to the prescriber's office SUNLENCA injections should be administered in a healthcare setting by a healthcare professional of the start Date is a structure of the start Date is a structure of the start Date is a structure of the st				
10. PRESCRIBE	R CERTIFICATION REQUIRED				
By signing this form, I certify that I am personally prescribing or furnishing Gilead medication for the patient identified in Section 3. I certify that this prescription medication is medically necessary for the patient and that it will be used as directed. I certify that I will be supervising or coordinating the patient's treatments, in accordance with law, and verify that the information provided as part of my patient's application for the Patient Assistance Program ("PAP") is complete and accurate to the best of my knowledge. I certify that I have not received and shall not seek reimbursement for any Gilead medication dispensed to the patient through the PAP from any government program or third-party insurer. If applicable, I certify that medication provided to me by the PAP for the eligible patient identified in Section 3 will be provided by me to such patient for his or her own use without charge. I certify that I will not otherwise use any such medication or prescribe, provide, furnish, or dispense all or any portion thereof to any other person or patient. I will notify Gilead if all or any portion of the medication provided to me by the aptient, and I will ensure such medication is returned to Gilead or its designated representative, by calling 1-800-226-2056 within 30 days. I certify that I will not sell, resell, offer for sale, trade, or barter medication provided to me under the PAP. Healthcare facility may be subject to audits by Gilead and its third-party audit firm. I consent that Gilead may perform random audits and verification related to: 1) the applicant identified in Section 3, including but not limited to confirming patient identify and verifying medical					
necessity; and 2) the dispensing of medication provided to the prescriber through the PAP, including confirming patient receipt of the prescribed Gilead medication and the timely return of any medications received for, but not dispensed to, the patient identified in Section 3, if applicable.					
I certify that I have received the appropriate written authorization from the patient, in accordance with the Health Insurance Portability and Accountability Act of 1996, applicable state health information privacy law(s), and any other applicable requirements, in order to release the patient's personal and medical information to Gilead and its agents and contractors for the purposes of assessing the patient's insurance coverage and eligibility for participation in Advancing Access, conducting random audits to verify the information provided on this enrollment form, and for other purposes as outlined in the Patient Authorization For Use and Disclosure of Personal Health Information in Section 6. Gilead is authorized to contact me about the information provided on this form and as needed to facilitate my patient's enrollment and participation in Advancing Access. I understand that Gilead may, if authorized by the patient, contact the patient directly to verify Advancing Access eligibility and updates to insurance coverage, as well as to confirm the receipt of Gilead medication through the PAP.					
I understand that completing this enrollment form does not guarantee that assistance will be provided to my patient. My patient has given consent for me to receive their Gilead medication on their behalf. I will receive and secure my patient's medication at my office until it's provided to my patient, when applicable. I will comply with and abide by my state practitioner dispensing laws for authorized prescribers, when applicable.					
SPECIAL NOTE: New York	k prescribers, please submit prescription on an original NY State prescription bl	ank. For all other states, if not faxe	ed, prescription must be on stat	e-specific blank if applicable for your state.	
REQUIRED X PRESCRIBER SIGNATURE (DISPENSE AS WRITTEN): DATE: / /					
(SIGN ONE) PRESCRIBER SIGNATURE (SUBSTITUTIONS ALLOWED): NO STAMP ALLOWED			DATE: / /		

GILEAD SUNLENCA, ADVANCING ACCESS, the ADVANCING ACCESS Logo, GILEAD, and the GILEAD Logo are trademarks of Gilead Sciences, Inc., or its related companies. © 2022 Gilead Sciences, Inc. All rights reserved. US-ADMP-0024 12/22

PRINT FORM

FAX COMPLETED FORM TO ADVANCING ACCESS AT 1-833-445-3234